Dr. T. O. Daniel

Biography

  Dr. Thomas O. Daniel, also known as Tom, M.D., serves as an Executive Vice President and President of Celgene Research & Early Development at Celgene Limited. Dr. Daniel serves as a Venture Partner of Arch Venture Partners, L.P. Dr. Daniel served as the President of Research & Early development of Celgene Corporation from December 2006 to January 2016 and also served as its Executive Vice President from February 15, 2012 to January 2016. Dr. Daniel has more than two decades of medical and pharmaceutical research experience and served as the Chief Scientific Officer at Ambrx, Inc. since September 2003. He served as the Vice President of Research at Amgen Inc., where he served as Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Dr. Daniel served as Senior Vice President of Discovery Research. He served as the President of Celgene Research at Celgene Corporation since December 2006. He served as Senior Vice President of Research at Immunex Corporation. At Immunex, he consolidated and built programs in oncology and vascular biology, advanced candidate therapeutics in those areas and forged programmatic emphasis on antibody therapeutics. He serves as Chairman of the Board at Vividion Therapeutics, Inc. Dr. Daniel served as the Chairman of Celgene Research of Celgene Corporation (also known as Celgene, Inc.) from January 2016 to March 1, 2016. He serves as a Director of ImmusanT, Inc., Vir Biotechnology, Inc., Vividion, Magenta Therapeutics, Inc. and FerruMax, Abide. He has been a Director at Juno Therapeutics, Inc. since August 2015. He has been an Independent Director of Zafgen, Inc. since March 3, 2016. He is Senior Advisor to BlackThorn Therapeutics. He has been a Member of Therapeutic Advisory Board at aTyr Pharma, Inc. since March 1, 2011. He served as Director of Ambrx, Inc. He served as a Director of Epizyme, Inc. from May 2012 to June 9, 2014. He served as Director of PharmAkea, Inc. A nephrologist and former academic investigator, Dr. Daniel was the K. M. Hakim Professor of Medicine and Cell Biology at Vanderbilt University and Director of the Vanderbilt Center for Vascular Biology. Dr. Daniel practiced nephrology, led research programs in the Vanderbilt-Ingram Cancer Center and co-directed the M.D./Ph.D. program. He trained in Internal Medicine at Massachusetts General Hospital, in molecular genetics with Michael Brown and Joseph Goldstein and a was recipient of NIH and HHMI research funding for over 20 years. He earned an M.D. from University of Texas, Southwestern.

Research Interest

Biomedicine